Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + fenofibric acid
- Development stage
- Phase 3
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atorvastatin + fenofibric acid is a combination medication used to treat mixed dyslipidemia. This combination targets multiple aspects of dyslipidemia by addressing both elevated LDL cholesterol and triglycerides while also helping to raise HDL cholesterol levels. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol production in the liver, while fenofibric acid is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and increase HDL cholesterol. Clinical studies have shown that this combination significantly improves lipid parameters compared to either medication alone.
- Brand names
- LCP-AtorFen
- Other names
- atorvastatin + fenofibrate
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on atorvastatin + fenofibric acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + fenofibric acid.